aflibercept

CHEBI:CHEBI_747743

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
aflibercept
rxcui
2693567
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
marketing_start_date
20111121
package_marketing_start_date
21-NOV-11
active_ingredient_strength
8 mg/.07mL
marketing_category
DRUG FOR FURTHER PROCESSING
route
INTRAVITREAL
labeler_name
Regeneron Pharmaceuticals, Inc.
manufacturer_name
Regeneron Pharmaceuticals, Inc.
product_ndc
61755-050
spl_id
10b670d6-52e0-4eba-953b-c839ffb98014
active_ingredient_name
AFLIBERCEPT
package_ndc
61755-050-51
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (61755-050-51) / .07 mL in 1 VIAL, SINGLE-DOSE (61755-050-50)
unii
15C2VL427D
nui
N0000193542
pharm_class_epc
Vascular Endothelial Growth Factor Inhibitor [EPC]
pharm_class
Vascular Endothelial Growth Factor Inhibitors [MoA]
pharm_class_moa
Vascular Endothelial Growth Factor Inhibitors [MoA]
brand_name
EYLEA
brand_name_base
EYLEA
application_number
BLA125387
spl_set_id
f96cfd69-da34-41ee-90a9-610a4655cd1c
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class